Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis - PubMed

Affiliations

• PMID: 16606781
• DOI: 10.1001/archneur.63.4.614

Editorial

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis

E M Frohman et al. Arch Neurol. 2006 Apr.

Comment on

• Not every patient with multiple sclerosis should be treated at time of diagnosis.

  Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, Carter J, Shuster E, Rodriguez M. Pittock SJ, et al. Arch Neurol. 2006 Apr;63(4):611-4. doi: 10.1001/archneur.63.4.611. Arch Neurol. 2006. PMID: 16606780 No abstract available.

Similar articles

• Early treatment: PreCISe-ly what the patient needs.

  Montalban X. Montalban X. J Neurol Sci. 2009 Dec;287 Suppl 1:S2-6. doi: 10.1016/S0022-510X(09)71293-6. J Neurol Sci. 2009. PMID: 20106344

• Not every patient with multiple sclerosis should be treated at time of diagnosis.

  Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, Carter J, Shuster E, Rodriguez M. Pittock SJ, et al. Arch Neurol. 2006 Apr;63(4):611-4. doi: 10.1001/archneur.63.4.611. Arch Neurol. 2006. PMID: 16606780 No abstract available.

• Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event.

  Gout O, Bouchareine A, Moulignier A, Deschamps R, Papeix C, Gorochov G, Héran F, Bastuji-Garin S. Gout O, et al. Mult Scler. 2011 Feb;17(2):164-72. doi: 10.1177/1352458510385506. Epub 2010 Oct 21. Mult Scler. 2011. PMID: 20965960

• New options for early treatment of multiple sclerosis.

  Tintoré M. Tintoré M. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. J Neurol Sci. 2009. PMID: 19200870 Review.

• Management of worsening multiple sclerosis with mitoxantrone: a review.

  Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.

Cited by

• Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

  Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M. Lugaresi A, et al. Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24. Neuropsychiatr Dis Treat. 2013. PMID: 23836975 Free PMC article.

• The antibody genetics of multiple sclerosis: comparing next-generation sequencing to sanger sequencing.

  Rounds WH, Ligocki AJ, Levin MK, Greenberg BM, Bigwood DW, Eastman EM, Cowell LG, Monson NL. Rounds WH, et al. Front Neurol. 2014 Sep 16;5:166. doi: 10.3389/fneur.2014.00166. eCollection 2014. Front Neurol. 2014. PMID: 25278930 Free PMC article.

• The use of immune modulating drugs for the treatment of multiple sclerosis.

  Al-Khamis FA. Al-Khamis FA. Neurosciences (Riyadh). 2016 Jan;21(1):4-9. doi: 10.17712/nsj.2016.1.20150252. Neurosciences (Riyadh). 2016. PMID: 26818160 Free PMC article. Review.

• Optic Neuritis: The Role of Disease-modifying Therapy in This Clinically Isolated Syndrome.

  Costello F. Costello F. Curr Treat Options Neurol. 2007 Jan;9(1):48-54. doi: 10.1007/s11940-007-0030-5. Curr Treat Options Neurol. 2007. PMID: 17288889

• Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

  Optic Neuritis Study Group. Optic Neuritis Study Group. Arch Neurol. 2008 Jun;65(6):727-32. doi: 10.1001/archneur.65.6.727. Arch Neurol. 2008. PMID: 18541792 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information